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A bstrac t
Deficiency of cytochrome c oxidase activity was established in a girl born to consanguineous parents. She showed symptoms of 
dysmaturity, generalized hypotonia, myoclonic seizures and progressive respiratory failure, leading to death on the seventh day of life. 
Structural abnormalities of the central nervous system consisted of severe cerebellar hypoplasia and optic nerve atrophy. Biochemical 
analysis of a muscle biopsy specimen demonstrated deficiency of cytochrome c oxidase activity. Cultured fibroblasts from this patient 
a lso  showed a selective decrease in the activity of cytochrome r oxidase, excluding a muscle-specific type of deficiency. Further 
investigations in cultured fibroblasts revealed that synthesis, assembly and stability of both the mitochondrial and the nuclear subunits of 
th e  enzyme were entirely normal. The steady-state concentration of cytochrome v oxidase in I he fibroblasts of the patient was also 
normal, suggesting that the kinetic properties of the enzyme were altered. Analysis of the kinetic parameters of cytochrome r  oxidase 
demonstrated an aberrant interaction between cytochrome c oxidase and its substrate, cytochrome a  most likely because of a mutation in
o n e  of the nuclear subunits of the enzyme.
's: Cytochrome c oxidase; Enzyme kinetics; Mitochondrial disease; Hneephalomyoputhy; F si; (Human)
1 . Introduction
c oxidase (complex IV) is the terminal 
enzym e of the respiratory chain. It catalyses the transfer of 
electrons from reduced cytochrome c to oxygen and con­
serves the free energy of this reaction by pumping protons
across the mitochondrial inner membrane. enzyme is
com posed of thirteen different subunits, of which the three 
largest ones are encoded by mitochondrial DNA (mtDNA). 
T h e  other ten subunits are products of nuclear genes that
Abbreviations: mtDNA, mitochondrial DNA; DME, Dulhecco's mod­
ified Eagle medium; PCS, fetal calf serum; PBS, phosphate-buffered
s a l in e .
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are .synthesized in the cytoplasm and trans
mitochondria where they are mature
and assembled with the mitochondrial subunits [I 
.subunits encoded by mtDNA constitute the catalytic core 
of the enzyme: they contain the binding site for cy­
tochrome r  and the prosthetic groups, and they are in-
volved in proton [2]. The
nuclearly encoded subunits have not yet been 
These subunits might be involved in the process of assem­
bly of a functional enzyme [3], and/or might bind 
that regulate the catalytic activity of the enzyme 
regulatory function is supported by the presence of mus
a in mam
r oxidase [8,^].
of cytochrome c se activity is
quently tn with
1 1 » ,  1 1  ].
d e s  can be classified in four main
, these deficien­
tes on the basis
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of the origin and function of the gene products that are 
involved in the biogenesis of the enzyme. In the first 
group, the deficiency is caused by mtDNA deletions (as is 
frequently the case in the Kearns-Sayre syndrome and 
chronic progressive external ophthalmoplegia), by deple­
tion of mtDNA, or by point mutations in mitochondrial 
tRNA genes [10,12]. These types of mtDNA aberration do 
not lead to selective loss of cytochrome c oxidase activity: 
the activity of the other enzyme complexes that contain 
subunits encoded by mtDNA will also be reduced. In the 
second group, the disorder is based on mutations of nu­
clear genes for proteins that are involved in mitochondrial 
biogenesis, for instance in import or assembly of nuclearly 
encoded mitochondrial proteins. Such disorders are proba­
bly rare, but when they occur cytochrome c oxidase will 
again not be affected exclusively [13]. The third group 
consists of deficiencies that are due to mutations in the 
mitochondrial genes for subunits of cytochrome c oxidase. 
So far, this type of defect has only been described in a 
preliminary paper [14]. The fourth group is formed by 
deficiencies due to mutations in nuclear genes encoding 
subunits of cytochrome c oxidase, or because of defects in 
the regulation of the expression of genes for the different 
isoforms. The latter type of defect has been proposed as an 
explanation for cases of benign, muscle-specific cy­
tochrome c oxidase deficiency [8,10], but experimental 
proof is still lacking. Many cases of Leigh’s syndrome are 
most likely based on defects in nuclear genes for subunits 
of cytochrome c oxidase that do not show tissue-specific 
expression [10,11,15], but the mutations in question have 
yet to be identified.
In general, the concentration of the enzyme is reduced 
in tissues or cultured cells from patients with a decreased 
cytochrome c oxidase activity [8,10,16], indicating that 
assembly or stability of the enzyme are affected. In con­
trast, here we describe a case of selective deficiency of 
cytochrome c oxidase where the amount of enzyme was 
entirely normal. However, the affinity of the enzyme for 
its substrate, cytochrome c, was significantly decreased. 
The results clearly suggest that mutations in the nuclear 
subunits can affect the catalytic activity of cytochrome c
oxidase.
malities than an elevated concentration of lactate acid in 
the cerebrospinal fluid. Magnetic resonance imaging on the 
fourth day of life showed marked hypoplasia of the cere­
bellum, in particular of the cerebellar hemispheres. The 
girl died at the age of seven days from progressive respira­
tory failure probably due to combined neuromuscular in­
sufficiency and cerebral dysfunction. Muscle and skin 
biopsy specimens were collected within 1 h after death and 
immediately processed for further analysis. Examination of 
the muscle tissue by light microscopy showed no ragged 
red fibres. Analysis of several mitochondrial enzymes in 
muscle homogenates revealed a selective decrease in the 
activity of cytochrome c oxidase.
2.2. Fibroblast cultures
Fibroblasts derived from the patient and from different 
healthy controls were cultured in Dulbecco’s modified 
Eagle medium (DME) containing 1 mM pyruvate and 
supplemented with 10% heat-inactivated fetal calf serum 
(FCS), at 37° C in a humidified atmosphere of 10% C 0 2 in 
air [16,17]. Cells from exponentially growing cultures were 
collected as described before [16,18]. The cell pellet was 
resuspended in phosphate buffered saline (PBS) and the 
cell concentration was determined using a counting cham­
ber. The cell suspension was divided in small portions, 
frozen in liquid nitrogen and stored at — 80° C.
2.3. Metabolic labeling
2. Materials and methods
2.1. Patient
After removing the normal culture medium, fibroblasts 
from exponentially growing cultures were rinsed twice 
with PBS and cultured in methionine-free DME containing
1 mM pyruvate and supplemented with 10% heat-in­
activated FCS in a humidified atmosphere of 10% C 0 2 in 
air. After 1 h, [35S]methionine (specific activity >960 
Ci/m m ol) was added to a final concentration of 20 /xCi 
per ml. At various time points, cells were collected by 
centrifugation as described above. In pulse-chase experi­
ments, the [35S]methionine containing medium was re­
placed by pre-incubated complete DME containing 1 mM 
pyruvate and 10% FCS after rinsing the cells four times 
with PBS. In a number of experiments, emetine was used 
to block the synthesis of nuclear-encoded proteins [19]. 
Emetine was added 10 min before the addition of labeled 
methionine, to a final concentration of 100 /xg/ml.
The clinical data of the patient will be described in 
detail elsewhere (P.G. Barth et al., unpublished data). In 
short, the female patient was born after an uneventful 
pregnancy as the first child to consanguineous (first 
cousins) parents of Moroc origin. Severe, persistent hypo­
tonia and myoclonic seizures were observed from the first 
day of life. Ophthalmoscopy revealed bilateral optic nerve 
atrophy. Laboratory investigations showed no other abnor-
2.4. Immunoprécipitation
The volume of samples containing about 5 • 106 fibrob­
lasts was adjusted to 1 ml with PBS containing 1 mg of 
bovine serum album in/m l and 2.5 mM phenylmethyl- 
sulphonyl fluoride. Lauryl maltoside (final concentration 
1.5%) was added to solubilize the cells and to extract 
membrane proteins. The samples were left on ice for 30 
min and then centrifuged for 1 min in a microfuge at
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12000 X g. The supernatants were used for immunoprecip- 
itation by incubation overnight with antibodies coupled to
4B
[16,18,20]. The immunoprecipitates were eluted by incu­
bating the beads in sample buffer (4% sodium dodecyl 
sulphate, 20% glycerol in 10 mM Tris-HCl, pH 6.8) at 
37° €  for 2 h. After centrifugation, the eluates were loaded 
on to 15% polyacrylamide gels and subjected to elec-
sis as described by Schiigger and Von Jagow [21]. 
In the case of metabolic labeling experiments, the gels 
were dried under vacuum and labeled proteins were visual­
ized by fluorography [22].
electrophoresis of “ S-Iabeled
a Phosphor I mager
i were qm on
Sunnyvale, USA)
stained by silver
2.5. Antisera
first dimension separation according to molecular mass of 
these large complexes occurs under native conditions, and 
in the second dimension where electrophoresis is per­
formed under denaturating conditions, the individual sub­
units of the complexes are resolved. Isolation of the com­
plexes prior to electrophoresis by for instance immuno­
précipitation is not required, which reduces the possibility 
of losing one or more subunits during isolation of a 
complex. Crude mitochondria were used as starting mate­
rial for two-dimensional electrophoresis, and were ob­
tained by incubating 1 • 106 cells/ml PBS for 10 min at 
4° C with 20 fig of digitonin [28,29]. The samples were 
centrifuged for 1 min at 12000 X g in a microfuge to 
obtain a mitochondrial pellet. The gels were stained with
[2 0 ].
2.7. Mitochondrial functions in fibroblasts
its I, II, and III of mammalian cytochrome c
mitochondrial genome, the
by nuclear
oxidase are encoded by 
remaining ten smaller subunits are 
genes. According to their elec 
referred to as subunits IV, Va, Vb, Via, VIb, Vic, Vila, 
Vllb, VIIc, and VIII, respectively [20]. Human cytochrome 
c oxidase occurs in two isoforms. One form is present in 
skeletal muscle and heart and contains muscle-type forms 
of subunits Via and Vila. The other form of cytochrome c 
oxidase is present in all other tissues, including cultured 
cells, and contains the so-called liver-type forms of sub­
units Via and Vila [8,9,20,23,24]. A polyclonal antiserum
bovine heart was raised 
antiserum have
in detail [16,18,20,25,26]. In s
ì assembled enzyme co
cell or tissue homogenates solubilized with lauryl malto- 
side: after immunoprécipitation and electrophoresis all the 
subunits are detectable with conventional staining meth-
unmunopree 
partial loss from
» r*i/»
mtiserum. The antiserum
arly encoded s
subunits (and s it VIII) are,
Ïmtiserum does not discriminate between both isoforms of
c
2.6. Two-dimensional electrophoresis
Two-dimensional electrophoresis was
a
Von Jagow (P. Klement et al.,
by Schiigger and 
data) [27]. This 
mass and
composition of (mitochondrial) enzyme complexes. In the
Mitochondrial ATP synthesis was measured in fibrob­
lasts from exponentially growing cultures, permeabilized 
with low concentrations of digitonin (1 jLtg/106 cells) 
[30]. ATP synthesis was initiated by the addition of ADP 
to a final concentration of 10 mM. Glutamate (10 mM) 4- 
malate (2 mM) or pyruvate (10 mM) 4- malate (2 mM) 
were used as substrates for oxidative phosphorylation via 
complexes I, III and IV. Succinate (10 mM) ( + 2 ¡xg 
rotenone/ml to inhibit complex I) was used as a substrate 
for oxidative phosphorylation via complexes II, III and IV. 
Ascorbate (10 mM) + tetramethylphenylenediamine (0.5 
mM) were used as substrates for ATP production via 
complex IV. In the latter case 2 jug rotenone/ml and 2 ¡xg 
antimycin/ml were present to inhibit the activities of 
complex I and III, respectively.
The activity of mitochondrial enzymes and the protein 
content of the cells were determined in freshly prepared 
cell lysates, obtained by treatment with lauryl maltoside as 
described under immunoprécipitation. The activity of cy­
tochrome c oxidase was measured spectrophotometrically
at 25° C in 25 mM phosphate buffer (pH 7.4), using 
20 (xM reduced bovine heart cytochrome c as the sub­
strate, and is as the first-order reaction-rate 
constant, k. The steady-state kinetics of the enzyme were 
measured under the same conditions, but the concentration 
of reduced cytochrome c was varied between 1 and 67 
fiM. The final concentration of cytochrome c oxidase in 
these measurements was calculated via quantitative im­
munoprécipitation as described before [20]. K m and 
values were determined for the high-affinity reaction by 
computer analysis of the data which were expressed as
reversed Eadie-Hofstee plots.
The citrate synthase activity was measured according to 
the method of Srere [31]. The activities of complex II and 
III were measured at 25° C in 25 mM phosphate buffer (pH 
7.4), containing 1 mM MgCl2. Succinate (10 mM) was 
used as substrate for measurements of complex II, where 
the reduction of dichlorophenolindophenol (50 /xM) was
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followed in the presence of rotenone (2 ¡xg /ml), an- 
timycin (2 /xg/m l) and KCN (2 mM). Antimycin (2 
/xg/ml) sensitive complex III activity was determined in 
the presence of both rotenone (2 ¿ug/ml) and KCN (2 
mM), using decylubiquinol (80 /zM) as substrate and 
oxidized bovine heart cytochrome c (40 ju-M) as electron 
acceptor. The enzymatic activities are expressed as 
nm ol/m g protein in cell lysates/min. The protein content 
of the samples was estimated using a modified Lowry 
method [32].
2.8. Sequencing o f the gene for subunit II
Mitochondrial DNA sequences were amplified by poly­
merase chain reaction from DNA isolated from fibroblasts 
of the patient. Primers were selected by means of computer 
program Primer (S.E. Lincoln, M.J. Daly and E.S. Lander, 
MIT Center for Genomic Research and Whitehead Insti­
tute for Biomedical Research, Cambridge, USA). Primers 
were synthesized on an Expedite Nucleic Acid Synthesis 
System™ (Milllipore, Bedford, USA). To amplify the 
mtDNA fragment corresponding to nucleotide number 
7578-8303 appropriate forward and reverse primers were 
synthesized, and to sequence this fragment internal primers 
(forward and reverse) for the nucleotide numbers 7771- 
7849 and 8009-8089. The polymerase chain reaction pro­
gram was: 95° C, 30 s; 55° C, 60 s; and 12° C, 90 s for 30 
cycles. The polymerase chain reaction products were puri­
fied by electrophoresis and recovered from the gel using 
Magic™ PCR Preps column (Promega, Madison, USA). 
The sequencing reactions were carried out according to
standard methods, using [35S]dATP and the T7 polymerase 
sequencing kit (Sequenase, USB, Cleveland, USA)
3. Results
3.1. Analysis of the activities of mitochondrial enzymes in 
cultured fibroblasts
The activity of cytochrome c oxidase in cultured fibro­
blasts from the patient, expressed per mg cellular protein, 
was 25% of the corresponding mean control value. The
normal (Table 1). Deficiency of cytochrome c oxidase 
activity was therefore not limited to muscle of the patient. 
This ruled out muscle-specificity of the primary defect, 
such as involvement of the muscle-type specific subunits 
Via and Vila. Furthermore, this allowed us to study the 
biosynthesis and other properties of the enzyme from the 
patient in detail.
3.2. Synthesis and assembly of cytochrome c oxidase
Fig. 1 shows the results of studies on the synthesis, 
assembly and degradation of subunits of cytochrome c 
oxidase in fibroblasts from the patient and in control 
fibroblasts. Experiments with intact cells labeled in the 
presence of emetine indicated that the expression of mito­
chondrial genes in fibroblasts from the patient was compa­
rable to that in control fibroblasts, both with respect to the 
amount of label incorporated into mitochondrial gene prod-
c o x
subunit
n  m
IV
VI
Fig. 1. Synthesis and stability of mitochondrial and nuclear subunits of cytochromc c oxidase in control fibroblasts and fibroblasts from the patient. 
Fibroblasts were labeled with [35S]methionine for 1 h or 2 h. After labeling for 2 h, the cells were cultured further in the absence of labeled methionine for 
3 h or 21 h. The subunits of cytochrome c oxidase were isolated by immunoprécipitation from cells solubilized with lauryl maltoside. The same number of 
cells (0.5 • 106) was used for each experiment. COX: cytochrome c oxidase.
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Mitochondrial functions in cultured fibroblasts
Enzyme activities
citrate synthase 79 (2) 78 (51; 58-80)
complex II 6.2 (2) 7.6 (9; 5.6-7.8)
complex III 9.6 (2) 10.7(7; 10.3-13.1)
complex IV 0.15 (2) 0.58 (51; 0.45-0.62)
ATP production
glutamate + malate 1355 (3) 1393 (7; 1104-1402)
pyruvate +  malate 1231 (3) 1239(6; 1056-1320)
succinate 977(3) 997(6;672-1116)
ascorbate +  TMPD 700 (2) 703 (3;688-725)
r n r ^ r - ~ i i i iT r'"rnn~ '‘m m ip ir tr i ï im in in n nT ïn irfirnw m fpn fïr in ii'i'iMi>iiipm iii>Min 4*n> «AM
The activity of mitochondrial enzymes were measured in fibroblasts 
solubilized with lauryl maltoside. The activities are expressed as k per 
min per mg protein (cytochrome c oxidase) or as nmol per min per mg 
protein (other enzymes), as described in Section 2. The ATP production 
was measured in fibroblasts permeabilized with digitonin and is ex­
pressed as nmol ATP per h per mg protein. The mean values obtained in 
different experiments are shown. The assays with fibroblasts from the 
patient were performed in duplicate, the number of independent experi­
ments is indicated between brackets. The assays with control fibroblasts 
were also performed in duplicate, the number of independent experiments 
and the minimal and maximal values obtained for various control fibrob­
lasts are given between brackets. TMPD: tetramethyl phenylenediamine.
ucts and with respect to the molecular mass of these 
products (data not shown). Immunoprécipitation of sub­
units of cytochrome c oxidase after labeling in the absence 
of emetine demonstrated that the rate of synthesis of 
nuclear subunits also did not differ significantly between 
fibroblasts from the patient and control fibroblasts (Fig. 1, 
pulse-experiments). The same was the case for the turnover 
rate of the subunits, determined in pulse-chase experiments 
(Fig. 1). Since the antiserum that was used only precipi­
tates mitochondrial subunits of cytochrome c oxidase when
these are assembled with nuclear subunits (see Section 2), 
the assembly of mitochondrial and nuclear subunits in cells 
from the patient was apparently normal: the ratio between 
the signals of, e.g., subunit II and IV was always compara­
ble to that seen in control cells at the same pulse or 
pulse-chase time.
3.3. Concentration of cytochrome c oxidase
Fig. 2 an example of two
trophoresis of mitochondrial enzyme complexes
trol fibroblasts and those from the patient, 
could be easily identified because of the mobility in the 
first dimension and the characteristic electrophoretic pat-
[27]. Intern of the subunits in the second 
addition, we confirmed the position of cytochrome c oxi
ase by of and
second-dimension gels; immunoreactivity was found only 
in the area where the assembled enzyme was expected 
because of its molecular mass. A comparison of the con­
centrations of complexes 1, II, III, IV, and V derived from 
the same number of control or patient’s fibroblasts showed 
no differences: the concentration of the complexes, includ­
ing that of complex IV, was normal in fibroblasts from the 
patient. Careful analysis of the staining intensity of the 
subunits of cytochrome c oxidase also did not 
significant differences in concentration of individual sub­
units between controls and the patient.
3.4. Mobility of nuclear subunits of cytochrome c oxidase
Minor m of individual
subunits of cytochrome c oxidase will not
P c
• : V . . ^ . p - . • . . . V .
•¡•of; - •
r - >. ^  ¿i i - : ■> -i '
.  • '  - V -
- . - y .  V ..
' .• VÆ’ f:;:.-V'
<,• i.Oï
........: i x  -; I : .
,  . . . . . . .
- - .I . . .  ■: . . .
unit
1
II III
IV
Va,b
Vla,b,c
~VlIa,b,c
-VIII
Fig. 2. Composition and concentration of mitochondrial enzyme 
by digitonin treatment of control fibroblasts (C) or fibroblasts 
stained by stiver. I, II, III, IV, V: complexes I, II, III, IV and V. The position of these c
s in control fibroblasts and fibroblasts from the patient. Mitochondria obtained
the patient (P) were used as starting material for 2D-cIeetrophorcsis. The gels were
s after electrophoresis in the first dimension is indicated at
the top. COX: cytochrome c  oxidase (complex IV). The position of the individual subunits of cytochrome c oxidase after electrophoresis in the second 
dimension is indicated on the right.
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under the experimental conditions used above. In view of 
this, longer gels on which a much higher degree of resolu­
tion can be obtained [18,20] were used to analyse the
»
mobility of the nuclear subunits. Before electrophoresis, 
cytochrome c oxidase was isolated from the same number 
of control and patient’s fibroblasts by immunoprécipita­
tion. The intensive staining of polypeptides derived from 
the antiserum in the upper part of the gel obscures the 
mitochondrial subunits [16,20], but the nuclear subunits 
were clearly visible and differences in mobility were not 
observed (Fig. 3). In addition, the concentration of the 
individual subunits as judged by silver staining was com­
parable between controls and patient, except for that of 
subunit VIII (Fig. 3, right side).
3,5. Kinetic analysis of cytochrome c oxidase
The steady-state kinetic reactions of cytochrome c oxi­
dase in fibroblasts from the patient and in control fibrob­
lasts are shown in the form of reverse Eadie-Hol’stee plots 
in Fig. 4. Under conditions of low ionic strength, biphasic 
plots are obtained for cytochrome c oxidase reactions that 
show a high-affinity and a low-affinity phase [20], but at
III-
IV
VI a b :  c _ * > .i i *
.  .. i.-;
.'■Vs ' 'v  'i-l'') .
VIII-
Fig. 3. Mobility of nuclear subunits of cytochrome c oxidase in control 
fibroblasts and fibroblasts from the patient. Cytochrome c oxidase was 
isolated from 8 - 106 control fibroblasts (C) or 8 * 106 fibroblasts from the 
patient (P) by immunoprécipitation. The gels were stained with silver. R: 
human heart cytochromc c oxidase, used as reference [20]. The position 
of the subunits of human cytochrome c oxidase is indicated on the left. In 
order to show subunit VIII more clearly, the right-hand part of Fig. 3 
shows an overexposed picture of the same gel as shown in the left part.
V (nmol/min/mg protein)
Fig. 4. Steady-state kinetics of cytochrome c oxidase in control fibro­
blasts and in fibroblasts from the patient. The activity of cytochrome c 
oxidase was measured in fibroblasts solubilized with lauryl maltoside at 
concentrations of reduced bovine heart cytochromc c that ranged from 1 
to 67 /iM. The rate of oxidation of cytochrome c is plotted against the 
oxidation rate at a given substrate concentration (reversed Eadie-Hofstee 
plots). The combined results of 2 independent experiments are shown, 
The lines indicate the reaction kinetics for the high-affinity phase, 
control fibroblasts; O: patient fibroblasts.
intermediate ionic strength as used here, the low-affinity 
phase tends to disappear. Analysis of the data shown in 
Fig. 4 resulted in a value of Vmax for the high-affinity 
reaction of 14 nmol per min per mg cell protein in control 
cells, in the patient it proved to be 6 nmol per min per mg 
protein. Analysis of the amount of cytochrome c oxidase 
using quantitative immunoprécipitation [20] showed that 1 
mg of cellular protein per ml equalled a cytochrome c 
oxidase concentration of 0.025 f iM, both in control fibrob­
lasts and in fibroblasts from the patient. Therefore, the 
maximal turnover number per molecule cytochrome c 
oxidase from control fibroblasts was 9.3 per s, and 4 per s 
for cytochrome c oxidase from the patient. Calculation of
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the K m values showed more significant differences: in 
control cells the K m of the enzyme for reduced bovine 
cytochrome c was 40 /xM whereas the K m for reduced 
cytochrome c of cytochrome c oxidase from the patient 
was increased to 160 uM .
3.6. Mitochondrial function
Table 1 shows that there were no differences between 
cells from the patient and control fibroblasts when their 
capacity for mitochondrial ATP production was compared. 
ATP production as the result of oxidation of NADH 
(derived from either glutamate or pyruvate) via complexes 
I, III and IV, and ATP production resulting from the 
oxidation of succinate via complexes II, III and IV was 
normal in the patient’s fibroblasts, indicating that the 
reduced activity of cytochrome c oxidase was not limiting 
in this respect. ATP production measured in the presence 
of inhibitors of complex I and complex III was also not 
affected when ascorbate +  tetramethylphenylenediamine 
were used as artificial electron donors for complex IV.
3.7. Sequence analysis of the gene for subunit II
The sequence of the gene for subunit II of cytochrome 
c oxidase from the patient proved to be identical to the 
Cambridge sequence [33].
4. Discussion
We identified selective deficiency of cytochrome c 
oxidase activity in a patient who presented shortly after 
birth with severe hypotonia and severe cerebellar hypopla­
sia and who died of progressive respiratory failure on the 
seventh day of life. The only major abnormality in the 
results of extensive clinical laboratory investigations was a 
moderately elevated level of lactate in the cerebrospinal 
fluid, compatible with mitochondrial dysfunction in brain 
tissue. The hypoplastic cerebellar hemispheres, docu­
mented by cranial magnetic resonance imaging, indicated 
that normal growth and development of the fetal brain 
were affected by the primary defect. Cerebellar hypoplasia 
can be caused by various metabolic and non-metabolic 
diseases [34], and the findings in this patient suggest that 
deficiency of cytochrome c oxidase may be another cause.
Studies in cultured fibroblasts from the patient showed 
also a selective deficiency of cytochrome c oxidase activ­
ity, but metabolic labeling experiments demonstrated that 
the rate of synthesis and turnover of mitochondrial and 
nuclear subunits of cytochrome c oxidase did not differ 
between patient and control cells, suggesting that the 
steady-state concentration of the enzyme complex was 
normal (Fig. 1). This was confirmed by the results from 
two-dimensional electrophoresis. The position of the as­
sembled enzyme complex after electrophoresis in the first
dimension was the same as that of normally-sized cy­
tochrome c oxidase and the steady-state concentration of 
individual subunits of cytochrome c oxidase, visualized by 
staining after electrophoresis in the second dimension, was 
comparable in fibroblasts from the patient and control cells 
(Fig. 2). The reduced activity of the enzyme in the patient 
was therefore not due to a reduced amount of complex IV, 
but to a diminished activity per molecule of the enzyme.
To investigate the diminished activity of cytochrome c 
oxidase from the patient in more detail, the kinetics of the 
reactions of the enzyme were studied. These studies were 
performed at intermediate ionic strength and the reactions 
were analyzed for the high-affinity phase, since these 
conditions are supposed to resemble the physiological 
situation [20,35,36], This analysis showed that the activity 
per molecule of enzyme (or turnover number) was indeed 
decreased in the patient, and, moreover, that the K m for 
reduced bovine cytochrome c was 4-fold increased (Fig. 
4). In view of the difficulty to obtain sufficient material for 
classical kinetic assays with purified mitochondrial en­
zymes from patients, the analyses were carried out with 
supernatants of cells treated with lauryl maltoside. Using 
the same approach, the kinetic parameters for human cy­
tochrome c oxidase from different tissues were compared 
in a previous study [20]. The values for K m and maximal 
turnover number per molecule enzyme obtained in that 
study for cytochrome c oxidase from, e.g., human kidney 
are well comparable to those found in the present study for 
control fibroblasts.
The activity of cytochrome c oxidase from the patient 
showed no abnormalities when ascorbate and tetramethyl 
phenylenediamine were used as artificial electron donors 
in experiments with permeabilized fibroblasts (Table 1). 
The interaction (binding and dissociation) of cytochrome c 
and cytochrome c oxidase is not rate-limiting for the 
activity under the latter conditions, whereas this is the case 
when activity measurements are carried out with cy­
tochrome c as substrate [36]. The reduction of cytochrome 
c oxidase activity in the patient is thus most probably 
related to defects in the interaction with cytochrome c and 
not caused by defects that influence the electron transfer or 
proton-pumping properties of the enzyme. The most obvi­
ous explanation for this would be a mutation in subunit II 
of the enzyme, since this subunit contains the cytochrome 
c binding site [37]. However, sequence analysis of the 
entire gene revealed no mutations, the genes for subunits I 
and III showed no major rearrangements, and the expres­
sion of all three mitochondrial genes for subunits of cy­
tochrome c oxidase was completely normal.
Alternatively, a mutation in a nuclear gene for one of 
the subunits of cytochrome c oxidase might be the cause 
of the aberrant kinetic parameters of the enzyme in the 
patient. This possibility would suggest an autosomal reces­
sive mutation. This could be in line with both the consan­
guinity of the parents of the patient and the birth of a 
second, healthy child. The postulated mutation in a nuclear
200 L.GJ. Nijtmans et al. / Biochimica et Biophysica Acta 1270 (1995) 193—201
subunit of the enzyme should indirectly influence the 
binding of cytochrome c to explain our findings. Possible 
regulation of the activity of cytochrome c oxidase by
roughly estimated. Differential tissue-involvement, as was 
the case in our patient, could reflect the different require­
ments for cytochrome c oxidase activity, or differences in
binding to the nuclear subunits of effectors such as nu~ the in vivo regulation of the activity of the enzyme. In
cleotides or hormones was proposed already a long time 
ago [38], and regulation of the activity of the mammalian
cultured fibroblasts, the deficiency did not lead to a re­
duced capacity for ATP production, suggesting that the
enzyme by binding of ATP to subunit Via has been 
demonstrated [39]. Possible differences in modulation by
reduced activity of cytochrome c oxidase was not limiting 
for this process. Since the patient did not show major
ATP binding can, however, not account for the different 
kinetics of cytochrome c oxidase from the patient, since
metabolic disturbances, the diminished cytochrome c oxi­
dase activity might likewise not have affected normal liver
the activity was normal when tested in the presence of 
ATP and ADP (in permeabilized cells), but abnormal in 
their absence (as measured with the solubilized enzyme).
function. The defect appeared, however, to influence mus­
cle function and especially the development of the cerebel­
lum.
Mutations of subunits Via and Vila can also be excluded, 
since deficiency of cytochrome c oxidase activity was
found both in cultured fibroblasts (containing the liver-type 
forms of these subunits) and in muscle (containing the
Acknowledgements
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tochrome c oxidase were the same in the patient and 
control (Fig. 3). Apparently, it also does not influence the 
assembly of the enzyme, since the steady-state concentra­
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